SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomized trial

DOI record: { "DOI": "10.1016/j.lansea.2022.100036", "ISSN": [ "2772-3682" ], "URL": "http://dx.doi.org/10.1016/j.lansea.2022.100036", "alternative-id": [ "S2772368222000464" ], "article-number": "100036", "author": [ { "affiliation": [], "family": "Tandon", "given": "Monika", "sequence": "first" }, { "affiliation": [], "family": "Wu", "given": "Wen", "sequence": "additional" }, { "affiliation": [], "family": "Moore", "given": "Keith", "sequence": "additional" }, { "affiliation": [], "family": "Winchester", "given": "Stephen", "sequence": "additional" }, { "affiliation": [], "family": "Tu", "given": "Yuan-Po", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-5697-2779", "affiliation": [], "authenticated-orcid": false, "family": "Miller", "given": "Christopher", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0003-1701-2115", "affiliation": [], "authenticated-orcid": false, "family": "Kodgule", "given": "Rahul", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0001-6333-7098", "affiliation": [], "authenticated-orcid": false, "family": "Pendse", "given": "Amol", "sequence": "additional" }, { "affiliation": [], "family": "Rangwala", "given": "Shabbir", "sequence": "additional" }, { "affiliation": [], "family": "Joshi", "given": "Shashank", "sequence": "additional" } ], "container-title": "The Lancet Regional Health - Southeast Asia", "container-title-short": "The Lancet Regional Health - Southeast Asia", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2022, 6, 29 ] ], "date-time": "2022-06-29T06:31:35Z", "timestamp": 1656484295000 }, "deposited": { "date-parts": [ [ 2022, 7, 13 ] ], "date-time": "2022-07-13T06:23:48Z", "timestamp": 1657693428000 }, "indexed": { "date-parts": [ [ 2022, 7, 13 ] ], "date-time": "2022-07-13T06:41:44Z", "timestamp": 1657694504651 }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2022, 6 ] ] }, "language": "en", "license": [ { "URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 6, 1 ] ], "date-time": "2022-06-01T00:00:00Z", "timestamp": 1654041600000 } }, { "URL": "http://creativecommons.org/licenses/by/4.0/", "content-version": "vor", "delay-in-days": 24, "start": { "date-parts": [ [ 2022, 6, 25 ] ], "date-time": "2022-06-25T00:00:00Z", "timestamp": 1656115200000 } } ], "link": [ { "URL": "https://api.elsevier.com/content/article/PII:S2772368222000464?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://api.elsevier.com/content/article/PII:S2772368222000464?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining" } ], "member": "78", "original-title": [], "page": "100036", "prefix": "10.1016", "published": { "date-parts": [ [ 2022, 6 ] ] }, "published-print": { "date-parts": [ [ 2022, 6 ] ] }, "publisher": "Elsevier BV", "reference": [ { "key": "10.1016/j.lansea.2022.100036_bib0001", "unstructured": "World Health Organization. Coronavirus (COVID-19) Dashboard. https://covid19.who.int/. Accessed 1 March 2022" }, { "DOI": "10.1016/j.jinf.2021.05.009", "article-title": "Clinical efficacy of nitric oxide nasal spray (NONS) for the treatment of mild COVID-19 infection", "author": "Winchester", "doi-asserted-by": "crossref", "first-page": "237", "issue": "2", "journal-title": "J Infect", "key": "10.1016/j.lansea.2022.100036_bib0002", "volume": "83", "year": "2021" }, { "DOI": "10.1016/j.redox.2020.101734", "article-title": "Mitigation of the replication of SARS-CoV-2 by nitric oxide in vitro", "author": "Akaberi", "doi-asserted-by": "crossref", "journal-title": "Redox Biol", "key": "10.1016/j.lansea.2022.100036_bib0003", "volume": "37", "year": "2020" }, { "DOI": "10.1111/j.1365-2362.1991.tb01383.x", "article-title": "Endogenous nitric oxide: physiology, pathology, and clinical relevance", "author": "Moncada", "doi-asserted-by": "crossref", "first-page": "361", "issue": "4", "journal-title": "Eur J Clin Invest", "key": "10.1016/j.lansea.2022.100036_bib0004", "volume": "21", "year": "1991" }, { "DOI": "10.1172/JCI119473", "article-title": "Perspectives series: host/pathogen interactions. Mechanisms of nitric oxide-related antimicrobial activity", "author": "Fang", "doi-asserted-by": "crossref", "first-page": "2818", "issue": "12", "journal-title": "J Clin Invest", "key": "10.1016/j.lansea.2022.100036_bib0005", "volume": "99", "year": "1997" }, { "DOI": "10.1016/j.niox.2013.03.007", "article-title": "Gaseous nitric oxide reduces influenza infectivity in vitro", "author": "Regev-Shoshani", "doi-asserted-by": "crossref", "first-page": "48", "journal-title": "Nitric Oxide", "key": "10.1016/j.lansea.2022.100036_bib0006", "volume": "31", "year": "2013" }, { "DOI": "10.1016/j.virol.2009.09.007", "article-title": "Dual effect of nitric oxide on SARS-CoV replication: viral RNA production and palmitoylation of the S protein are affected", "author": "Åkerström", "doi-asserted-by": "crossref", "first-page": "1", "issue": "1", "journal-title": "Virology", "key": "10.1016/j.lansea.2022.100036_bib0007", "volume": "395", "year": "2009" }, { "key": "10.1016/j.lansea.2022.100036_bib0008", "series-title": "Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment Guidance for Industry", "year": "2020" }, { "DOI": "10.1016/S1473-3099(20)30483-7", "article-title": "A minimal common outcome measure set for COVID-19 clinical research", "doi-asserted-by": "crossref", "first-page": "e192", "journal-title": "Lancet Infect Dis", "key": "10.1016/j.lansea.2022.100036_bib0009", "volume": "20", "year": "2020" }, { "key": "10.1016/j.lansea.2022.100036_bib0010", "unstructured": "Yeh S Using trapezoidal rule for the area under a curve calculation. SAS Conference Proceedings: SAS User Group International Conference (SUGI) -27, 2002, Paper 229-27.https://support.sas.com/resources/papers/proceedings/proceedings/sugi27/p229-27.pdf. Accessed 21 May 2021." }, { "DOI": "10.1038/s41591-022-01679-5", "article-title": "Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial", "author": "Pajon", "doi-asserted-by": "crossref", "first-page": "823", "journal-title": "Nat Med", "key": "10.1016/j.lansea.2022.100036_bib0011", "volume": "28", "year": "2022" }, { "DOI": "10.1126/science.abf6950", "article-title": "Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape", "author": "McCarthy", "doi-asserted-by": "crossref", "first-page": "1139", "journal-title": "Science", "key": "10.1016/j.lansea.2022.100036_bib0012", "volume": "371", "year": "2021" }, { "DOI": "10.1016/j.chom.2021.06.006", "article-title": "SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity", "author": "Motozono", "doi-asserted-by": "crossref", "first-page": "1124", "issue": "7", "journal-title": "Cell Host Microbe", "key": "10.1016/j.lansea.2022.100036_bib0013", "volume": "27", "year": "2021" }, { "DOI": "10.3389/fcimb.2021.781429", "article-title": "SARS-COV-2 variants: differences and potential of immune evasion", "author": "Hirabara", "doi-asserted-by": "crossref", "first-page": "1", "journal-title": "Front Cell Infect Microbiol", "key": "10.1016/j.lansea.2022.100036_bib0014", "volume": "11", "year": "2022" }, { "DOI": "10.1056/NEJMoa2108163", "article-title": "REGEN-COV antibody combination and outcomes in outpatients with COVID-19", "author": "Weinreich", "doi-asserted-by": "crossref", "first-page": "e81", "journal-title": "N Engl J Med", "key": "10.1016/j.lansea.2022.100036_bib0015", "volume": "385", "year": "2021" }, { "key": "10.1016/j.lansea.2022.100036_bib0016", "unstructured": "Pfizer Press Release. Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate in reducing risk of hospitalization or death, 14 December 2021. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results. Accessed 18 February 2022." }, { "DOI": "10.3390/v12040372", "article-title": "Virology, epidemiology, pathogenesis, and control of COVID-19", "author": "Jin", "doi-asserted-by": "crossref", "first-page": "372", "issue": "4", "journal-title": "Viruses", "key": "10.1016/j.lansea.2022.100036_bib0017", "volume": "12", "year": "2020" }, { "DOI": "10.1007/s00405-021-06644-5", "article-title": "A sprayable Acid‑Oxidizing solution containing hypochlorous acid (AOS2020) efficiently and safely inactivates SARS‑Cov‑2: a new potential solution for upper respiratory tract hygiene", "author": "Giarratana", "doi-asserted-by": "crossref", "first-page": "3099", "journal-title": "Eur Archi Oto-Rhino-Laryngology", "key": "10.1016/j.lansea.2022.100036_bib0018", "volume": "278", "year": "2021" }, { "DOI": "10.1056/NEJMc2001737", "article-title": "SARS-CoV-2 viral load in upper respiratory specimens of infected patients", "author": "Zou", "doi-asserted-by": "crossref", "first-page": "1177", "issue": "12", "journal-title": "N Engl J Med", "key": "10.1016/j.lansea.2022.100036_bib0019", "volume": "382", "year": "2020" }, { "DOI": "10.1186/s13054-020-02893-8", "article-title": "SARSCoV-2 viral load in sputum correlates with risk of COVID-19 progression", "author": "Yu", "doi-asserted-by": "crossref", "first-page": "170", "issue": "1", "journal-title": "Crit Care", "key": "10.1016/j.lansea.2022.100036_bib0020", "volume": "24", "year": "2020" }, { "DOI": "10.1002/advs.202003895", "article-title": "Nitric oxide to fight viral infections", "author": "Lisi", "doi-asserted-by": "crossref", "first-page": "1", "journal-title": "Adv Sci", "key": "10.1016/j.lansea.2022.100036_bib0021", "volume": "8", "year": "2021" }, { "DOI": "10.21037/ajo-21-40", "article-title": "In vivo (human) and in vitro inactivation of SARS-CoV-2 with 0.5% povidone-iodine nasal spray", "author": "Friedland", "doi-asserted-by": "crossref", "first-page": "2", "journal-title": "Aust J Otolaryng", "key": "10.1016/j.lansea.2022.100036_bib0022", "volume": "5", "year": "2022" }, { "key": "10.1016/j.lansea.2022.100036_bib0023", "unstructured": "Utah State University Institute for Antiviral Research.Virucidal assay against Influenza A, HRV-14, and RSV. Report 2021-098. June 25, 2021 [data on file]." }, { "key": "10.1016/j.lansea.2022.100036_bib0024", "unstructured": "COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at: https://www.covid19treatmentguidelines.nih.gov/. Accessed 15 April 2022." }, { "key": "10.1016/j.lansea.2022.100036_bib0025", "unstructured": "SaNOtize study report - control test of NONS formulation against H1N1 [2021, data on file]." } ], "reference-count": 25, "references-count": 25, "relation": {}, "resource": { "primary": { "URL": "https://linkinghub.elsevier.com/retrieve/pii/S2772368222000464" } }, "score": 1, "short-title": [], "source": "Crossref", "subtitle": [], "title": "SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomized trial", "type": "journal-article" }